Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays
作者:Nilanjan Adhikari、Amit K. Halder、Sumana Mallick、Achintya Saha、Kishna D. Saha、Tarun Jha
DOI:10.1016/j.bmc.2016.07.023
日期:2016.9
of MMP-2 inhibitors over MMP-9. Bayesian model fingerprints were used to design selective lead molecule which was modified using structure-based de novo technique. A series of designed molecules were prepared and screened initially for inhibitions of MMP-2 and MMP-9, respectively, as these are designed followed by other MMPs to observe the broader selectivity. The best active MMP-2 inhibitor had IC50
广泛的选择性严重限制了用于临床目的的基质金属蛋白酶2(MMP-2)抑制剂的开发。为了开发有效的和选择性的MMP-2抑制剂,最初采用了多种分子建模技术来进行可靠的设计。使用预测性和经过验证的回归模型(2D和3D QSAR和基于配体的药效团作图研究)来估计效价,而分类模型(贝叶斯和递归分配分析)用于确定MMP-2抑制剂对MMP-9的选择性。贝叶斯模型指纹用于设计选择性先导分子,并使用基于结构的从头技术对其进行修饰。制备了一系列设计的分子,并分别针对MMP-2和MMP-9的抑制作用进行了筛选,因为这些是紧随其他MMP之后设计的,以观察到更广泛的选择性。最佳活性MMP-2抑制剂的IC50值为24nM,而最佳选择性抑制剂(IC50 = 51nM)对所有测试的MMP表现出对MMP-2的选择性是至少4倍。活性衍生物对人肺癌细胞系A549无细胞毒性。在非细胞毒性浓度下,这些抑制剂最多可将细胞内MMP-2表